These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 12849008)

  • 1. Autoantibodies to IGF-II mRNA binding protein p62 and overexpression of p62 in human hepatocellular carcinoma.
    Zhang J; Chan EK
    Autoimmun Rev; 2002 May; 1(3):146-53. PubMed ID: 12849008
    [TBL] [Abstract][Full Text] [Related]  

  • 2. De-novo humoral immune responses to cancer-associated autoantigens during transition from chronic liver disease to hepatocellular carcinoma.
    Zhang JY; Zhu W; Imai H; Kiyosawa K; Chan EK; Tan EM
    Clin Exp Immunol; 2001 Jul; 125(1):3-9. PubMed ID: 11472419
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel cytoplasmic protein with RNA-binding motifs is an autoantigen in human hepatocellular carcinoma.
    Zhang JY; Chan EK; Peng XX; Tan EM
    J Exp Med; 1999 Apr; 189(7):1101-10. PubMed ID: 10190901
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aberrant expression of fetal RNA-binding protein p62 in liver cancer and liver cirrhosis.
    Lu M; Nakamura RM; Dent ED; Zhang JY; Nielsen FC; Christiansen J; Chan EK; Tan EM
    Am J Pathol; 2001 Sep; 159(3):945-53. PubMed ID: 11549587
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cloning and characterization of a novel 90 kDa 'companion' auto-antigen of p62 overexpressed in cancer.
    Soo Hoo L; Zhang JY; Chan EK
    Oncogene; 2002 Jul; 21(32):5006-15. PubMed ID: 12118381
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Significance of autoantibodies against insulin-like growth factor II mRNA-binding proteins in patients with hepatocellular carcinoma.
    Himoto T; Kuriyama S; Zhang JY; Chan EK; Nishioka M; Tan EM
    Int J Oncol; 2005 Feb; 26(2):311-7. PubMed ID: 15645114
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Autoantibody responses in Chinese hepatocellular carcinoma.
    Zhang JY; Wang X; Peng XX; Chan EK
    J Clin Immunol; 2002 Mar; 22(2):98-105. PubMed ID: 11998899
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The diversity expression of p62 in digestive system cancers.
    Su Y; Qian H; Zhang J; Wang S; Shi P; Peng X
    Clin Immunol; 2005 Aug; 116(2):118-23. PubMed ID: 15886058
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Benign autoimmunity to combat malignancy.
    Stauss HJ
    Clin Exp Immunol; 2001 Jul; 125(1):1-2. PubMed ID: 11472418
    [No Abstract]   [Full Text] [Related]  

  • 10. Antibody detection using tumor-associated antigen mini-array in immunodiagnosing human hepatocellular carcinoma.
    Zhang JY; Megliorino R; Peng XX; Tan EM; Chen Y; Chan EK
    J Hepatol; 2007 Jan; 46(1):107-14. PubMed ID: 17067715
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Large scale identification of human hepatocellular carcinoma-associated antigens by autoantibodies.
    Wang Y; Han KJ; Pang XW; Vaughan HA; Qu W; Dong XY; Peng JR; Zhao HT; Rui JA; Leng XS; Cebon J; Burgess AW; Chen WF
    J Immunol; 2002 Jul; 169(2):1102-9. PubMed ID: 12097419
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Autoantibodies in viral hepatitis-related hepatocellular carcinoma.
    Imai H; Kiyosawa K; Chan EK; Tan EM
    Intervirology; 1993; 35(1-4):73-85. PubMed ID: 8407252
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of all-trans-retinoic acid on mRNA binding protein p62 in human gastric cancer cells.
    Ping S; Wang S; Zhang J; Peng X
    Int J Biochem Cell Biol; 2005 Mar; 37(3):616-27. PubMed ID: 15618018
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increasing titers and changing specificities of antinuclear antibodies in patients with chronic liver disease who develop hepatocellular carcinoma.
    Imai H; Nakano Y; Kiyosawa K; Tan EM
    Cancer; 1993 Jan; 71(1):26-35. PubMed ID: 8380118
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Autoantibodies against glucose-regulated protein 78 as serological biomarkers in metastatic and recurrent hepatocellular carcinoma.
    Ying X; Han SX; He CC; Zhou CY; Dong YP; Cai MJ; Sui X; Ma CX; Sun X; Zhang YY; Gou WL; Mason C; Zhu Q
    Oncotarget; 2017 Apr; 8(15):24828-24839. PubMed ID: 28186997
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nucleolar antigens and autoantibodies in hepatocellular carcinoma and other malignancies.
    Imai H; Ochs RL; Kiyosawa K; Furuta S; Nakamura RM; Tan EM
    Am J Pathol; 1992 Apr; 140(4):859-70. PubMed ID: 1314027
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Autoimmune responses to mRNA binding proteins p62 and Koc in diverse malignancies.
    Zhang JY; Chan EK; Peng XX; Lu M; Wang X; Mueller F; Tan EM
    Clin Immunol; 2001 Aug; 100(2):149-56. PubMed ID: 11465943
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Screening of autoantibodies as potential biomarkers for hepatocellular carcinoma by using T7 phase display system.
    Liu H; Zhang J; Wang S; Pang Z; Wang Z; Zhou W; Wu M
    Cancer Epidemiol; 2012 Feb; 36(1):82-8. PubMed ID: 22018955
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IGF2 Is Up-regulated by Epigenetic Mechanisms in Hepatocellular Carcinomas and Is an Actionable Oncogene Product in Experimental Models.
    Martinez-Quetglas I; Pinyol R; Dauch D; Torrecilla S; Tovar V; Moeini A; Alsinet C; Portela A; Rodriguez-Carunchio L; Solé M; Lujambio A; Villanueva A; Thung S; Esteller M; Zender L; Llovet JM
    Gastroenterology; 2016 Dec; 151(6):1192-1205. PubMed ID: 27614046
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diversity of antinuclear antibody responses in hepatocellular carcinoma.
    Covini G; von Mühlen CA; Pacchetti S; Colombo M; Chan EK; Tan EM
    J Hepatol; 1997 Jun; 26(6):1255-65. PubMed ID: 9210612
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.